JP2016513105A - 改変グリコシル化を有するセツキシマブおよびその使用 - Google Patents

改変グリコシル化を有するセツキシマブおよびその使用 Download PDF

Info

Publication number
JP2016513105A
JP2016513105A JP2015557534A JP2015557534A JP2016513105A JP 2016513105 A JP2016513105 A JP 2016513105A JP 2015557534 A JP2015557534 A JP 2015557534A JP 2015557534 A JP2015557534 A JP 2015557534A JP 2016513105 A JP2016513105 A JP 2016513105A
Authority
JP
Japan
Prior art keywords
antibody
galactose
glycosylated
seq
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015557534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513105A5 (cg-RX-API-DMAC10.html
Inventor
エム ミード，ハリー
エム ミード，ハリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of JP2016513105A publication Critical patent/JP2016513105A/ja
Publication of JP2016513105A5 publication Critical patent/JP2016513105A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/102—Caprine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015557534A 2013-02-13 2014-02-13 改変グリコシル化を有するセツキシマブおよびその使用 Pending JP2016513105A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764446P 2013-02-13 2013-02-13
US61/764,446 2013-02-13
PCT/IB2014/000867 WO2014125382A2 (en) 2013-02-13 2014-02-13 Cetuximab with modified glycosylation and uses thereof

Publications (2)

Publication Number Publication Date
JP2016513105A true JP2016513105A (ja) 2016-05-12
JP2016513105A5 JP2016513105A5 (cg-RX-API-DMAC10.html) 2017-03-09

Family

ID=50980328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015557534A Pending JP2016513105A (ja) 2013-02-13 2014-02-13 改変グリコシル化を有するセツキシマブおよびその使用

Country Status (13)

Country Link
US (1) US20160002330A1 (cg-RX-API-DMAC10.html)
EP (1) EP2956484B1 (cg-RX-API-DMAC10.html)
JP (1) JP2016513105A (cg-RX-API-DMAC10.html)
KR (1) KR20150145225A (cg-RX-API-DMAC10.html)
CN (1) CN105358577A (cg-RX-API-DMAC10.html)
AR (1) AR094779A1 (cg-RX-API-DMAC10.html)
AU (1) AU2014217569B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015019339A2 (cg-RX-API-DMAC10.html)
CA (1) CA2900915A1 (cg-RX-API-DMAC10.html)
IL (1) IL240442A0 (cg-RX-API-DMAC10.html)
MX (1) MX2015010429A (cg-RX-API-DMAC10.html)
TW (1) TW201444871A (cg-RX-API-DMAC10.html)
WO (1) WO2014125382A2 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011350895B2 (en) 2010-12-30 2015-05-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
CA2916566A1 (fr) 2013-07-05 2015-01-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Matrice de chromatographie d'affinite
US10927384B2 (en) 2014-04-09 2021-02-23 Dna Twopointo Inc. DNA vectors, transposons and transposases for eukaryotic genome modification
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
LT3359671T (lt) 2015-10-08 2021-12-10 Dna Twopointo Inc. Dnr vektoriai, transpozonai ir transpozazės, skirti eukariotinio genomo modifikacijai
EP3400248A4 (en) * 2016-01-10 2019-09-04 Sorrento Therapeutics, Inc. IMPROVED SAFETY FOR THE TREATMENT OF CANCER WITH GLYCOSYLATED CHIMERIC ANTIBODY AGAINST EGFR
CN116333130A (zh) * 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
KR102376545B1 (ko) * 2017-08-01 2022-03-21 삼성디스플레이 주식회사 플렉시블 디스플레이 윈도우
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
WO2022148549A1 (en) 2020-01-14 2022-07-14 Babylat Gmbh Apparatus and method for obtaining protein-enriched fractions from breast milk

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085474A2 (en) * 2003-03-20 2004-10-07 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
JP2005525817A (ja) * 2002-05-17 2005-09-02 ヘマテック，エルエルシー ヒト抗体産生が可能なトランスジェニック有蹄動物
JP2009538885A (ja) * 2006-05-31 2009-11-12 エルエフビー バイオテクノロジース それぞれの分子が明確なグリカン単位を含む２つのｎ−グリコシル化部位を有する遺伝子組み換えあるいは形質転換因子ｖｉｉ組成物
JP2010502204A (ja) * 2006-09-10 2010-01-28 グリコトープ ゲーエムベーハー 抗体の発現のための骨髄白血病起源のヒト細胞の使用
WO2011060069A2 (en) * 2009-11-11 2011-05-19 Momenta Pharmaceuticals, Inc. Glycosyl transferase from chinese hamster and related methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
BR0316643A (pt) * 2002-11-27 2005-10-11 Gtc Biotherapeutics Inc Anticorpos modificados estavelmente produzidos no leite e método de produzir os mesmos
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
WO2008101177A2 (en) * 2007-02-16 2008-08-21 University Of Virginia Patent Foundation Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
JP2012515922A (ja) * 2009-01-22 2012-07-12 モメンタ ファーマシューティカルズ インコーポレイテッド ＣＨＯ細胞由来の糖タンパク質産物におけるガラクトース−α−１，３−ガラクトース含有Ｎ−グリカン

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525817A (ja) * 2002-05-17 2005-09-02 ヘマテック，エルエルシー ヒト抗体産生が可能なトランスジェニック有蹄動物
WO2004085474A2 (en) * 2003-03-20 2004-10-07 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
JP2009538885A (ja) * 2006-05-31 2009-11-12 エルエフビー バイオテクノロジース それぞれの分子が明確なグリカン単位を含む２つのｎ−グリコシル化部位を有する遺伝子組み換えあるいは形質転換因子ｖｉｉ組成物
JP2010502204A (ja) * 2006-09-10 2010-01-28 グリコトープ ゲーエムベーハー 抗体の発現のための骨髄白血病起源のヒト細胞の使用
WO2011060069A2 (en) * 2009-11-11 2011-05-19 Momenta Pharmaceuticals, Inc. Glycosyl transferase from chinese hamster and related methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAUMEISTER H, JOURNAL OF BIOTECHNOLOGY, JPN5009014312, November 2004 (2004-11-01), NL, pages 10 - 11, ISSN: 0004122940 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 358, no. 11, JPN6018003952, 13 March 2008 (2008-03-13), pages 1109 - 1117, ISSN: 0004122941 *

Also Published As

Publication number Publication date
US20160002330A1 (en) 2016-01-07
WO2014125382A2 (en) 2014-08-21
KR20150145225A (ko) 2015-12-29
IL240442A0 (en) 2015-09-24
TW201444871A (zh) 2014-12-01
AR094779A1 (es) 2015-08-26
EP2956484A2 (en) 2015-12-23
AU2014217569A1 (en) 2015-08-27
WO2014125382A3 (en) 2014-11-06
EP2956484B1 (en) 2018-11-14
CA2900915A1 (en) 2014-08-21
CN105358577A (zh) 2016-02-24
BR112015019339A2 (pt) 2017-08-22
AU2014217569B2 (en) 2018-10-25
MX2015010429A (es) 2016-05-16

Similar Documents

Publication Publication Date Title
EP2956484B1 (en) Cetuximab with modified glycosylation and uses thereof
ES2755181T3 (es) Anticuerpos anti-TNF-alfa altamente galactosilados y usos de los mismos
US20260102485A1 (en) Neutralizing anti-tl1a monoclonal antibodies
JP3523245B1 (ja) ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US7838041B2 (en) Method for treating multiple myeloma
JP2021527110A (ja) ＣＤ４７とＳＩＲＰａの相互作用を遮断できる抗体及びその応用
JP2020125286A (ja) 高ガラクトシル化抗ｈｅｒ２抗体およびその使用
JP2006507839A (ja) 乳中に安定して産生される改変抗体およびその製造方法
JP2002544238A (ja) 抗−ＥｒｂＢ２抗体による治療
CN102766210A (zh) 人ctla-4抗体及其应用
JP2003516718A (ja) ＨＥＲ２／ｎｅｕに対するヒトモノクローナル抗体
JP2017537653A (ja) トランスジェニックマウス
KR20090114350A (ko) 형질전환 동물에서의 중쇄만의 항체의 생성
KR20170040132A (ko) Fc 단편의 제조
WO2002008442A2 (en) Means and methods for raising antibody concentration in compartments of the body of a non human animal
EP4512423A1 (en) Therapeutic agent for nk cell tumor
HK40017293A (en) Antibody capable of binding to myelin oligodendrocyte glycoprotein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191002